核心观点2024 年,公司实现9.81 亿元总收入,同比增长342%,同时产品收入为2.41 亿元,同比增长52%,收入表现符合预期。2024年,公司的核心管线奥雷巴替尼与武田达成全球合作,成功出海,同时TKI 耐药后的CML-CP 成功进入医保,产品2025 年放量值得期待。同时,APG2575 国内外临床持续稳步推进,产品后续可期。总体看,2024 年公司国内外业务发展出色,后续值得期待。事件...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
If the download button clicks without skipping, click on the top right menu and select "Open in Browser."